Safety of Bisphosphonates in the Treatment of Osteoporosis

Robert R. Recker, E. Michael Lewiecki, Paul D. Miller, James Reiffel

Research output: Contribution to journalArticlepeer-review

83 Scopus citations


In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).

Original languageEnglish (US)
Pages (from-to)S22-S32
JournalAmerican Journal of Medicine
Issue number2 SUPPL.
StatePublished - 2009

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Safety of Bisphosphonates in the Treatment of Osteoporosis'. Together they form a unique fingerprint.

Cite this